0001209191-18-024989.txt : 20180416
0001209191-18-024989.hdr.sgml : 20180416
20180416162345
ACCESSION NUMBER: 0001209191-18-024989
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180412
FILED AS OF DATE: 20180416
DATE AS OF CHANGE: 20180416
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schwieterman William D
CENTRAL INDEX KEY: 0001403961
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-21990
FILM NUMBER: 18756861
MAIL ADDRESS:
STREET 1: C/O OXIGENE, INC., 230 THIRD AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MATEON THERAPEUTICS INC
CENTRAL INDEX KEY: 0000908259
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 133679168
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 701 GATEWAY BLVD.
STREET 2: SUITE 210
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-635-7000
MAIL ADDRESS:
STREET 1: 701 GATEWAY BLVD.
STREET 2: SUITE 210
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: OXIGENE INC
DATE OF NAME CHANGE: 19930628
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-04-12
0
0000908259
MATEON THERAPEUTICS INC
MATN
0001403961
Schwieterman William D
C/O MATEON THERAPEUTICS, INC.
701 GATEWAY BLVD., SUITE 210
SOUTH SAN FRANCISCO
CA
94080
1
1
0
0
President and CEO
Common Stock
2018-04-12
4
P
0
625000
A
625747
D
Common Stock A Warrant (Right to Buy)
0.40
2018-04-12
4
P
0
312500
A
2018-04-12
2020-04-12
Common Stock
312500
312500
D
Common Stock B Warrant (Right to Buy)
0.40
2018-04-12
4
P
0
312500
A
Common Stock
312500
312500
D
The reported securities are included within 2.5 Units purchased by the reporting person for $50,000 per Unit pursuant to a Subscription Agreement between the reporting person and Mateon Therapeutics, Inc. (the "Company"), dated April 12, 2018 (the "Subscription Agreement"). Each Unit consists of (i) 250,000 shares of Common Stock of the Company, par value $0.01 per share (the "Common Stock"), (ii) an "A" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share and (iii) a "B" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share.
The Common Stock B Warrants shall become exercisable immediately following the Company's stockholders' approval of an increase in the number of the Company's authorized shares of Common Stock sufficient to cover the number of shares issuable upon the exercise of all of the Common Stock B Warrants (the "Stock Authorization"). The Company is obligated to effect the Stock Authorization no later than June 30, 2018 (the "Authorization Date").
The Common Stock B Warrants shall expire on the date that is two years after the Stock Authorization is effected (the "Expiration Date"). In the event that the Company fails to effect the Stock Authorization by the Authorization Date, the Expiration Date will be extended for two additional years.
/s/ Megan N. Gates, attorney-in-fact
2018-04-16